BC Week In Review | Feb 22, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BC Extra | Feb 20, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BC Week In Review | May 4, 2018
Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
BC Extra | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
BC Week In Review | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
BC Week In Review | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....
BC Extra | Sep 9, 2015
Financial News

Selecta raises $38M in series E

Selecta Biosciences Inc. (Watertown, Mass.) raised $38 million in a series E round led by existing investor OrbiMed. New investors Sanofi Genzyme Bioventures; Ridgeback Capital Management; Osage Partners; Aju IB Investment; and Sphera Global Health...
BC Extra | Sep 4, 2015
Company News

Management tracks

Gene therapy play Genenta Science s.r.l. (Milan, Italy) named Tiziana Mattioni COO. Mattioni was director and global program leader in oncology at Merck KGaA (Xetra:MRK). Newco Faraday Pharmaceuticals Inc. (Seattle, Wash.) named Stephen Hill CEO....
BC Week In Review | Aug 24, 2015
Company News

Catalyst Biosciences, Targacept deal

Catalyst completed its merger with Targacept to form new company Catalyst Biosciences Inc. (see BioCentury, April 6). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif.   Targacept Inc. , Winston-Salem, N.C.   Business: Hematology, Gastrointestinal  ...
BC Week In Review | May 11, 2015
Company News

Catalyst Biosciences, Wyeth deal

Pfizer Inc. (NYSE:PFE, New York, N.Y.) will exercise its right to terminate a 2009 deal granting Wyeth, now part of Pfizer, an exclusive, worldwide license to develop and commercialize the biotech’s PF-05280602 for bleeding in...
Items per page:
1 - 10 of 291
BC Week In Review | Feb 22, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BC Extra | Feb 20, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BC Week In Review | May 4, 2018
Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
BC Extra | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
BC Week In Review | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
BC Week In Review | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....
BC Extra | Sep 9, 2015
Financial News

Selecta raises $38M in series E

Selecta Biosciences Inc. (Watertown, Mass.) raised $38 million in a series E round led by existing investor OrbiMed. New investors Sanofi Genzyme Bioventures; Ridgeback Capital Management; Osage Partners; Aju IB Investment; and Sphera Global Health...
BC Extra | Sep 4, 2015
Company News

Management tracks

Gene therapy play Genenta Science s.r.l. (Milan, Italy) named Tiziana Mattioni COO. Mattioni was director and global program leader in oncology at Merck KGaA (Xetra:MRK). Newco Faraday Pharmaceuticals Inc. (Seattle, Wash.) named Stephen Hill CEO....
BC Week In Review | Aug 24, 2015
Company News

Catalyst Biosciences, Targacept deal

Catalyst completed its merger with Targacept to form new company Catalyst Biosciences Inc. (see BioCentury, April 6). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif.   Targacept Inc. , Winston-Salem, N.C.   Business: Hematology, Gastrointestinal  ...
BC Week In Review | May 11, 2015
Company News

Catalyst Biosciences, Wyeth deal

Pfizer Inc. (NYSE:PFE, New York, N.Y.) will exercise its right to terminate a 2009 deal granting Wyeth, now part of Pfizer, an exclusive, worldwide license to develop and commercialize the biotech’s PF-05280602 for bleeding in...
Items per page:
1 - 10 of 291